In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.

Christina A Sutherland,Jamie E Verastegui,David P Nicolau

doi:10.1186/s12941-016-0155-z

Christina A Sutherland, Jamie E Verastegui + Show 1 more

Open Access

https://doi.org/10.1186/s12941-016-0155-z

Copy DOI

Abstract

BackgroundThe purpose of this study was to define the potency of amikacin and comparator agents against a collection of blood and respiratory nosocomial isolates implicated in ICU based pulmonary infections gathered from US hospitals.MethodsMinimum inhibitory concentrations of amikacin, aztreonam, cefepime, ceftazidime, ceftolozane/tazobactam, ceftriaxone, ciprofloxacin, imipenem, meropenem, piperacillin/tazobactam and tobramycin were tested against 2460 Gram-negative isolates. Amikacin had 96 % susceptibility against the combined E. coli and K. pneumoniae isolates and 95 % susceptibility against P. aeruginosa.ResultsNinety-six percent of all of isolates tested were susceptible (i.e., MICs ≤16 mg/L) to amikacin by current laboratory standards which demonstrates a high level of activity to combat infections caused by these organisms including ESBL, MDR, β-lactam and fluoroquinolone resistant strains. Moreover, 99 % of all organisms had amikacin MICs ≤64 mg/L.ConclusionsOverall, these data highlight the continued potency of amikacin and suggest that the achievable lung concentrations of approximately 5000 mg/L with the administration of the amikacin by inhalation (Amikacin Inhale, BAY41-6551) will exceed the MICs typically observed for P. aeruginosa, E. coli and K. pneumoniae in the hospital setting.

Highlights

The purpose of this study was to define the potency of amikacin and comparator agents against a collection of blood and respiratory nosocomial isolates implicated in intensive care unit (ICU) based pulmonary infections gathered from US hospitals
Overall, these data highlight the continued potency of amikacin and suggest that the achievable lung concentrations of approximately 5000 mg/L with the administration of the amikacin by inhalation (Amikacin Inhale, BAY41-6551) will exceed the MICs typically observed for P. aeruginosa, E. coli and K. pneumoniae in the hospital setting
In this study we defined the phenotypic profile of amikacin against 2460 blood and respiratory nosocomial isolates implicated in ICU based pulmonary infections collected from 50 US hospitals

Summary

Introduction

The purpose of this study was to define the potency of amikacin and comparator agents against a collection of blood and respiratory nosocomial isolates implicated in ICU based pulmonary infections gathered from US hospitals. The management of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) has been made increasingly difficult due to the emergence of resistance and the potential for reduced antibiotic lung penetration in the intubated patient. HAP continues to be the second most common cause of nosocomial infections in the United States and is associated with increases in hospital length of stay, healthcare costs and represents a major cause of mortality especially in critically ill patients [1, 2]. Pseudomonas aeruginosa, along with the Enterobacteriacae, Escherichia coli and Klebsiella pneumoniae are amongst the most common etiological organisms representing approximately two-thirds of causative agents [4, 5]. Nosocomial pneumonia caused by P. aeruginosa, E. coli and K

Objectives

Methods

Results

Discussion

Conclusion